人類偏肺病毒 (hMPV) 治療市場按治療類型、給藥途徑、最終用戶、分銷管道和地區分類

Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type, By Route of Administration, By End User, By Distribution Channel, By Geography

出版日期: 2025年04月29日 | 出版商:

Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球人類偏肺病毒 (hMPV) 治療市場規模估計為 4.941 億美元，預計到 2032 年將達到 7.677 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 6.5%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	4.941億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	6.50%	2032年價值預測	7.677億美元

圖。 2025年人類偏肺病毒（hMPV）治療藥物市場佔有率（%）

人類亞肺病毒 (hMPV) 是一種高度傳染性的呼吸道病毒病原體，在感染疾病引起上呼吸道和下感染疾病。 hMP 病毒於 2001 年在荷蘭一名幼兒的呼吸道感染疾病中首次被發現。自此，hMPV 被世界公認為兒童和免疫力缺乏患者急性呼吸道感染疾病的重要病毒病原體。由於 hMPV 與其他呼吸道病毒（如呼吸道融合細胞病毒(RSV)）有相似之處，因此 hMPV感染疾病經常被漏診或誤診。然而，分子診斷技術的最新進展提高了我們對 hMPV 流行病學和疾病負擔的認知。由於目前尚無核准的疫苗或治療方法，隨著替代治療方法活性化力度的加大，人類亞肺病毒 (hMPv) 治療市場預計將在未來幾年內大幅成長。

市場動態：

全球人類偏肺病毒 (hMPV) 治療市場受到疾病盛行率上升、缺乏核准的治療方案、正在進行的候選藥物研發活動以及疫苗開發公共和私人資金增加的推動。然而，開發新藥的成本高、疫苗開發的成功率難以預測以及臨床試驗的潛在挑戰可能會抑制市場成長。該市場還為公司提供了機會，透過持續的發現研究來識別新藥，透過孤兒藥指定專注於兒科適應症，並與學術機構合作進行藥物開發。向呼吸系統疾病負擔日益加重的新興市場進行地理擴張將進一步補充長期的商業機會。此外，診斷方法的創新、感染動力學的研究以及聯合治療的開發都有可能擴大市場。

本研究的主要特點

本報告對全球人類偏肺病毒 (hMPV) 治療市場進行了詳細分析，並提供了預測期 (2025-2032) 的市場規模和年複合成長率（CAGR%），以 2024 年為基準年。
它揭示了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球人類偏肺病毒 (hMPV) 治療市場中的主要企業是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行分析的。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
全球人類偏肺病毒 (hMPV) 治療市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 494.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.50%	2032 Value Projection:	USD 767.7 Mn

Human metapneumovirus (hMPV) is a highly contagious respiratory viral pathogen that causes upper and lower respiratory tract infections worldwide. It was first identified in 2001 in young Dutch children with respiratory tract infections. Since then, hMPV has been recognized as an important viral agent of acute respiratory tract infection in pediatric patients and immuno-compromised individuals globally. Due to its close similarity to other respiratory viruses like respiratory syncytial virus (RSV), hMPV infections often remain undiagnosed or misdiagnosed. However, recent advances in molecular diagnostic techniques have enhanced understanding of hMPV epidemiology and disease burden. With no approved vaccines or treatments currently available, the human metapneumovirus (hmpv) therapeutics market is poised to grow significantly in the coming years as research efforts to develop therapeutic alternatives gain momentum.

Market Dynamics:

The global human metapneumovirus (hMPV) therapeutics market is driven by rising disease prevalence, lack of approved treatment options, ongoing research & development activities for drug candidates, and growing public-private funding for vaccine development. However, high development costs for new drugs, unpredictable success rate for vaccine development, and potential challenges in clinical trials can restrain market growth. The market also presents opportunities for players through ongoing discovery & research to identify novel drugs, focus on pediatric indication with orphan drug designation, and collaborations with academic institutions for drug development. Geographic expansion into emerging markets with growing respiratory disease burden will further supplement business opportunities in the long run. Innovation in diagnostics, research on transmission dynamics, and development of combination therapies also hold promise to expand the market size.

Key Features of the Study:

This report provides in-depth analysis of the global human metapneumovirus (hMPV) therapeutics market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human metapneumovirus (hMPV) therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK (GlaxoSmithKline), Merck & Co., Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson, Roche Holding AG, AstraZeneca PLC, AbbVie Inc., Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Amgen Inc., Eli Lilly and Company, Bayer AG, and Biogen Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global human metapneumovirus (hMPV) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

Treatment Type Insights (Revenue, USD Mn, 2020 - 2032)
- Antiviral Drugs
- Nucleotide analogs
- Protease inhibitors
- Polymerase inhibitors
- Vaccines
- Live-attenuated vaccines
- Inactivated vaccines
- Recombinant vaccines
- Supportive Therapies
- Monoclonal antibodies
- Immunomodulators
Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Intravenous
- Inhalation
End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals and Clinics
- Diagnostic and Reference Laboratories
- Academic and Research Institutions
- Others
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
- GSK (GlaxoSmithKline)
- Merck & Co.
- Pfizer Inc.
- Novartis AG
- Sanofi S.A.
- Johnson & Johnson
- Roche Holding AG
- AstraZeneca PLC
- AbbVie Inc.
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- Amgen Inc.
- Eli Lilly and Company
- Bayer AG
- Biogen Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Route of Administration
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By End User
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Nucleotide analogs
Protease inhibitors
Polymerase inhibitors
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Live-attenuated vaccines
Inactivated vaccines
Recombinant vaccines
Supportive Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Monoclonal antibodies
Immunomodulators

5. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Route of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Human Metapneumovirus (hMPV) Therapeutics Market, By End User, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Diagnostic and Reference Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Academic and Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region 2020 - 2032, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
Pfizer Inc.
Novartis AG
Sanofi S.A.
Johnson & Johnson
Roche Holding AG
AstraZeneca PLC
AbbVie Inc.
Regeneron Pharmaceuticals
Takeda Pharmaceutical Company
Amgen Inc.
Eli Lilly and Company
Bayer AG
Biogen Inc.